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Circulating concentrations of tumor necrosis factor-a (TNF), interleukin (IL)-l/?, IL-6, IL-1 
receptor antagonist (IL-lra), and soluble TNF receptors p55 (sTNFr-55) and p75 (sTNFr-75) 
and ex vivo production of TNF, IL-1, IL-6, and IL-lra using a whole blood culture system were 
measured during the acute and convalescent stages of meningococcal infection. Circulating TNF 
and IL-1 were below detection level, whereas IL-6 and IL-lra, sTNFr-55, and sTNFr-75 were 
increased at admission. The ex vivo production of proinflammatory cytokines TNF, IL-1, and 
IL-6 was suppressed at admission and restored gradually during recovery. On the contrary, the 
production of the antiinflammatory IL-lra was increased at admission. The elevated concentra­
tions of both IL-1 ra and sTNFr early in the course of infection suggest a regulatory role for these 
antiinflammatory compounds. The observed down-regulation of the ex vivo production of TNF, 
IL-1, and IL-6 and up-regulation of the production of IL-lra in the acute stage may indicate a 
protective regulation mechanism.
On contact with gram-negative bacteria or endotoxin (lipo- 
polysaccharide. LPS), the immune-apparatus responds with 
the production o f  a broad spectrum of cytokines. After injec­
tion o f  LPS in human volunteers, the plasma concentrations 
o f  the proinflammatory cytokines tumor necrosis factor-« 
(TNF), interleukin (lL)-l/3, and IL-6 and the antiinflamma­
tory IL-1 receptor antagonist ( IL -1 ra) rapidly increase [1-3], 
Furthermore, the plasma concentrations o f  soluble T N F re­
ceptors p55 (sTNFr-55) and p75 (sTNFr-75) also rise [4, 5].
Proinflammatory cytokines are thought to be essential for 
an adequate host defense. However, excessive production of 
T N F and IL-1 causes shock, and high plasma concentrations 
o f  TNF, IL-1, and IL-6 are associated with high mortality 
rates [6-10]. This deleterious action of the proinflammatory 
cytokines is balanced by sTNFr and IL-lra. Soluble TNF 
receptors prevent the inflammatory effects o f  TN F by bind­
ing to TNF. High sTN Fr/TN F plasma ratios were found to 
be associated with a better prognosis [5, 1 1]. IL-lra blocks 
the proinflammatory action of IL-1 by competitive binding 
to the IL-1 receptor [ 12]; infusion of IL-lra in experimental 
shock prevents the shock and improves survival [13-15]. A 
high production o f  IL-lra during the acute stage of an infec­
tion may therefore be beneficial.
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The principle sources o f  these cytokines are blood mono­
cytes and tissue macrophages. On incubation with LPS, iso­
lated monocytes or whole blood taken from healthy donors 
produce ex vivo cytokines in a spectrum similar to that ob­
served after LPS injection in volunteers. Without LPS stimu­
lation, there is no or minimal ex vivo cytokine production 
[16, 17]. Several investigators have reported that during the 
acute stage o f  serious infections, the ex vivo production of  
T N F and IL-1 is depressed [18-21]. The cause o f  this im­
paired production is unknown, but it has been considered as 
a down-regulated state o f  the cytokine-producing cells, possi­
bly reflecting a protective mechanism by averting high con­
centrations o f  these cytokines [19, 21]. This hypothesis 
would be supported if the production o f  the antiinflamma­
tory cytokine IL-lra were inversely regulated and increased 
during the acute stage.
We describe the pattern o f  circulating TNF, IL-1, IL-6, 
IL-1 ra, sTNFr-55, and sTNFr-75 and the ex vivo production 
o f  TNF, IL-1, IL-6, and IL-lra during meningococcal infec­
tion.
Patients and Methods
Five patients with bacteriologically proven acute meningococ­
cal infections, admitted to our intensive care unit, were studied. 
Four patients had meningitis without severe hemodynamic 
complications, and 1 (patient 2 ) had mild sepsis without menin­
gitis. Some clinical parameters indicating the severity of disease 
and prognosis are summarized in table 1. All patients received 
antibiotics. Dexamethasone was given in different doses over 
1-7 days (table 1). Patient 2 was also treated with two exchange 
transfusions [22]. All patients recovered completely, except pa­
tient 3 who developed sensorineural deafness.
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Table 1. Characteristics of the patients with meningococcal infections at admission and their dexamethasone therapy.
Patient no., 
sex/age (years)
Disease period 
before 
hospitalization
(H)
Blood 
pressure 
(mm Hg)
Arterial HCOJ 
concentration 
(mmol/L)
Leukocytes in 
cerebrospinal 
fluid (X I0 6/L)
Leukocytes in 
peripheral blood 
(X109/L)
Plasma
endotoxin
concentration
(P g /m L )
Dexamethasone therapy
Duration Dose 
(days) (mg/kg/day)
1. F/3 18 100/55 20.0 24.320 30.9 <12.5 3.5 1.000
2. F/5 16 80/50 16.9 1 1 7.3 162 4 0.600
3. M/6 36 1 10/85 17.0 13,800 19.2 <12.5 7 0.800
4. M/15 18 110/80 16.0 10.000 20.0 21 1.5 0.400
5. F/20 24 120/78 15.3 13,500 29.8 283 1 0.130
Serial plasma and serum samples were collected shortly after 
admission and daily for 6 days. For endotoxin measurements, 2 
mL of blood was drawn into 5-mL pyrogen-free plastic vials 
(Falcon; Becton Dickinson Labware, Lincoln Park. NJ) contain­
ing 50 1U of pyrogen-free heparin and centrifuged at 200 g for
10 min. Plasma for cytokine assays was drawn into 4-mL tubes 
(Vacutainer System; Becton Dickinson, Rutherford, NJ) con­
taining 48 /¿L of 15% EDTA(K3) and 250 /iL of aprotinin 
(10,000 kallikrein-inactivating units/mL; Bayer, Leverkusen, 
Germany). The tubes were centrifuged immediately at 2250 g 
for 10 min and then at 1 5,000 g for 5 min to remove the plate­
lets. For IL-6 measurements serum was used. Aliquots were 
stored at —20°C until assay.
The ex vivo production of cytokines was measured in whole 
blood using similar 4-mL tubes [23]. One tube was incubated 
without LPS; in the other, 50 ¿¿L of LPS (final concentration, 10 
Mg/mL; Escherichia coli 055;B5; Sigma, St Louis) was added 
under sterile conditions. After 24 h of incubation at 37°C. both 
tubes were centrifuged and handled as described above.
Endotoxin was measured in platelet-rich plasma by a chromo- 
genic limulus amoebocyte lysate assay (KabiVitrum, Stock­
holm). TNF was determined by RIA as described by Van der 
Meer et al. [24] (detection level, 100 pg/mL). IL-1 was mea­
sured by RIA according to Lisi et al. [25] without chloroform 
extraction (detection level, 80 pg/mL). IL-6 was measured by 
ELISA as delineated by Barrera et al. [26] (detection level, 20 
pg/mL). IL-lra was determined by RIA according to Poutsiaka 
et al. [17] (detection level, 300 pg/mL). sTNFr were measured 
by an enzyme-linked immunobinding assay (Hoflmann-La 
Roche; detection level, 80 pg/mL for sTNFr-55 and 300 pg/mL 
for sTNFr-75); normal values measured in 19 healthy volun­
teers were 1470 ± 190 pg/mL (median ± SD) for sTNFr-55 and 
2520 ± 660 pg/mL for sTNFr-75. To minimize analytical 
errors, all samples from the same patient were analyzed in the 
same run in duplicate.
Results
Circulating cytokines and sTNFr. The plasma concentra­
tions o f  T N F and IL-1 were below detection level in all sam­
ples. At admission, IL-6 (range, 365-2550  pg/mL; median, 
860), IL-lra (range, 2840-4680  pg/mL; median, 3740), 
sTNFr-55 (range, 2782-5215  pg/mL; median, 3873), and 
sTNFr-75 (range, 5700-17282 pg/mL; median, 12910)
were increased (figure 1). Within 2 days, these concentra­
tions fell to normal levels.
Ex vivo cytokine production. The ex vivo production of 
TN F without LPS stimulation was below detection level in 
all samples. With LPS stimulation, TN F production was be­
low detection level during the acute stage o f  the disease. 
After 3 days, during convalescence, this production gradu­
ally recovered to 810-3430 pg/mL (median, 2260) at day 6 
(figure 2 ).
The course o f  IL-1 production showed a similar pattern: 
no measurable production at admission and restored LPS- 
stimulated production during recovery at day 6 (range, 945-  
4300 pg/mL; median, 2325).
IL-6 was detectable at admission in unstimulated and in 
LPS-stimulated tubes. However, after correction for the cir­
culating serum concentrations, the ex vivo production o f  IL-
6 at admission was negligible. Similar to the pattern o f  ex 
vivo production o f  TN F and IL-1, the LPS-stimulated pro­
duction o f  IL-6 was restored during recovery, reaching 165— 
9000 pg/mL (median, 2850) at day 6.
The ex vivo production o f  IL-lra followed a different pat­
tern. At admission, the production of IL-1 ra in both unstimu­
lated and LPS-stimulated cultures appeared to be increased. 
The concentration at day 0 in the unstimulated tubes ranged 
from 4450 to 65 10 pg/mL (median, 5570); in the LPS-stimu­
lated tubes, this was 7080-12,990 pg/mL (median, 11,140). 
The LPS-stimulated production decreased during the next 2 
days toward a stable median o f  6710 pg/mL from day 2 to 
day 6. The unstimulated production declined gradually to­
ward a median o f  1 140 pg/mL at days 4-6.
The ex vivo production o f  sTNFr was not measured be­
cause previous studies demonstrated that TN F receptors 
were only minimally released in the whole blood culture sys­
tem on LPS stimulation (data not shown).
A similar pattern o f  ex vivo production was observed in all 
patients, regardless o f  their leukocyte number or corticoste­
roid dose. Thus, the observed pattern in ex vivo cytokine 
production was not influenced by these parameters.
Discussion
We followed the concentrations o f  circulating cytokines 
and their ex vivo production during the course o f  meningo­
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Figure 1. C ircu la t ing  cy tokine  
concen tra t ions  an d  their inhibitors  
dur ing  course o f  disease. T u m o r  
necrosis factor-a  ( T N F )  a n d  in ter­
leukin (IL)-I/3 were below de tec ­
tion levels (respectively, 100 and  
80 p g /m L )  in all sam ples  a n d  there­
fore are not shown. Left; pa t terns  
o f IL -6  ( • ) an d  IL-1 recep tor  an tag ­
onist (O). Right: courses o f  soluble  
T N F  receptors p55 ( • )  an d  p75 
(O). M edian  values have been in­
terpolated.
days after hospital acfrnission
coccal infections. The onset o f  acute meningococcal infec­
tions is abrupt, with a rather short disease period before hospi­
talization. As such, meningococcal infections resemble 
experimental models using endotoxin challenge.
In our patients, circulating T N F and IL-1 concentrations 
were all below detection level. Several factors may be respon­
sible for this negative finding. It may be possible that we 
missed the initial cytokinemia. The disease period before ad­
mission ranged from 16 to 36 h, and it is known that after 
LPS injection in human volunteers, T N F and IL-1 levels 
peak within 90-180  min [1, 2]. From clinical studies, we 
know that high TN F concentrations occur early during se­
vere meningococcal infections [8-10]. The relatively low en-
4
dotoxin concentrations at admission, the good prognostic 
score, and the absence o f  shock in 4 o f  the 5 patients may 
also explain the low TN F and IL-1 concentrations [8-10, 27,
28]. Finally, a slight increase in T N F and IL-1 could have 
been missed because o f  the relatively high detection level of 
our assays. Recently, we have been able to detect rapidly 
declining T N F and IL-1 concentrations early in the course of 
very severe and lethal meningococcal disease (unpublished 
data). In the present series, actual activation o f  the cytokine
network was documented by elevated concentrations o f  IL-
6. Furthermore, the increased sTNFr-55 and sTNFr-75 lev­
els are compatible with TN F activity on target cells in tissues, 
because binding o f  TN F to its receptors on these cells leads 
to shedding o f  the extramembranous part of the receptor [5,
29]. IL-lra concentrations were also elevated during the 
acute stage. The high concentrations o f  both sTNFr and IL- 
Ira early in the course o f  the infection suggest a regulating 
role for these antiinflammatory compounds.
The LPS-stimulated ex vivo production o f  the proinflam- 
matory cytokines TNF, IL-1, and IL-6 was suppressed during 
the acute stage. Gradually the production capacity was re­
stored during reconvalescence. In contrast, the capacity to 
produce ex vivo IL-lra was regulated inversely (figure 2). 
The LPS-stimulated IL-lra production was maximal during 
the acute stage and reached stability after 2 days. Moreover, 
in the unstimulated cultures at admission, a spontaneous pro­
duction o f  IL-lra was observed, which gradually decreased 
during convalescence.
We used a whole blood culture system to measure the ex 
vivo cytokine production. In vitro studies with isolated pe­
ripheral blood mononuclear cells (PBMC) or monocytes
Figure 2. Ex vivo cy tok ine  p ro ­
duc t ion  o f  tu m o r  necrosis factor-«  
( T N F ) ,  in ter leukin  (IL)-l/?, IL-6 
a n d  IL-1 recep tor  an tagon is t  (IL- 
lra )  dur ing  course o f  disease. Left: 
m ed ian  co n cen tra t io n s  (n =  5) in 
w hole  b lood cu ltu res  after  24 h 
ex vivo incuba t ion  w ithou t  lipo- 
polysaccharide  (LPS) s t im ula t ion .  
Right: m edian  co n cen tra t ions  after 
incuba t ion  with 10 Mg/m L LPS.
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have yielded a substantial part o f  our knowledge of the cyto­
kine response to infectious stimuli. However, isolation of 
PBMC requires large blood volumes and is laborious and 
difficult to organize. Whole blood culture systems are a suit­
able alternative in these circumstances [23, 30-32]. In addi­
tion, the whole blood system represents the cytokine re­
sponse o f all types of cells present in blood at a certain time 
point and may therefore be a more realistic assessment than 
measurements using a fixed number o f isolated and cultured 
cells.
Impaired ex vivo production o f the proinflammatory cyto­
kines TNF and IL-1 during acute infection has been reported 
by others [18-21]. Our study confirms these observations 
but also shows that the impaired capacity to produce proin- 
fiammatory cytokines does not indicate that the cells present 
in blood are completely refractory in terms of cytokine pro­
duction. Rather, they seem to have switched from a mainly 
proinflammatory action (as in healthy individuals) to an an­
tiinflammatory' action. During recovery, the cells gradually 
switch again to the balanced proinflammatory status.
Further research should be done on the mechanism be­
hind this programmed switch. Our findings in meningococ­
cal infection may represent a process similar to endotoxin 
tolerance, the phenomenon that survival in experimental an­
imals is markedly increased if a lethal dose o f endotoxin is 
preceded by a smaller dose. Inhibition o f the production of  
TNF, IL-1, and IL-6 is regarded as crucial [33]. Similarly, in 
human volunteers receiving endotoxin intravenously, the ex 
vivo production by CD14+ cells o f TNF, IL-1, and IL-6 is 
significantly decreased [34]. IL-4 and IL-10 may play a role 
in this process. IL-10 and IL-4 both down-regulate the LPS- 
stimulated production by human PBMC and monocytes of  
TNF, IL-1, and IL-6 , whereas preincubation with IL-4 in­
creases the synthesis o f IL-lra [35-37]. Better insight into 
these regulatory mechanisms may enable us to understand 
why in some patients the invasion in the bloodstream of  
Neisseria meningitidis induces high plasma concentrations of  
TNF, IL-1, and IL-6 with severe shock, whereas in others a 
localized meningitis develops with low systemic concentra­
tions of these cytokines [8-10]. Further study on these regula­
tory mechanisms may provide new therapeutic interven­
tions.
In conclusion, antiinflammatory compounds such as 
sTNFr and IL-lra are present in the circulation during early 
meningococcal infection. The down-regulation o f the pro­
duction o f TNF, IL-1, and IL-6 and up-regulation of the 
production of IL-lra during acute infection could serve as a 
mechanism o f protection.
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